[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100390804":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":69,"collaborators":32,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":32,"enrollmentInfo":82,"targetDuration":32,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase I - Gastric Cancer","EXPERIMENTAL","The research study procedures include:\n\n* Screening for eligibility\n* Study treatment including evaluations\n* MR-image guided radiation will be administered per disease site standards.\n* Follow up visits\n* Questionnaires",[13],"Radiation: Viewray MRIdian® Linac",{"label":15,"type":10,"description":11,"interventionNames":16},"Phase I - Breast Cancer",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Phase I - Mantle Cell Lymphoma",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Phase I - Larynx",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Phase I - Bladder",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"RADIATION","Viewray MRIdian® Linac","MR-image guided radiation will be administered per disease site standards.",[24,15,9,21,18],null,[34],{"name":35,"affiliation":36,"role":37},"Raymond Mak, MD","Dana-Farber Cancer Institute","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},"CONTACT","6177328651","rmak@partners.org",[44,61],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Brigham & Women's Hospital","RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-71.05977,42.35843,{"lat":56,"lon":55},[59,60],{"name":35,"role":40,"phone":32,"phoneExt":32,"email":32},{"name":35,"role":37,"phone":32,"phoneExt":32,"email":32},{"facility":62,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Dana Farber Cancer Institute",{"type":53,"coordinates":64},[55,56],{"lat":56,"lon":55},[67,68],{"name":35,"role":40,"phone":32,"phoneExt":32,"email":32},{"name":35,"role":37,"phone":32,"phoneExt":32,"email":32},{"type":37,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Raymond Mak","Principal Investigator","100390804","confirm-magnetic-resonance-guided-radiation-therapy-100390804",false,"NCT04368702","CONFIRM: Magnetic Resonance Guided Radiation Therapy","Clinical Onboard Utilization of Image Guided Radiation Therapy With Magnetic Resonance (CONFIRM): A Master Protocol","CONFIRM","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed malignancy requiring radiation\n* Age 18 years of older\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Any further criteria listed in the specific disease site cohort\n\nExclusion Criteria\n\n* History of allergic reactions attributed to gadolinium-based IV contrast\n\n  \\-- Note: If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility\n* Severe claustrophobia or anxiety\n* Participants who cannot undergo an MRI\n* Any other exclusion criteria listed in the specific disease site cohort","ALL","18 Years",{"count":83,"type":84},70,"ESTIMATED","INTERVENTIONAL",[87],"NA","This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.",[90,91,92,93,94,95],"Gastric Cancer","Invasive Breast Cancer","in Situ Breast Cancer","Mantle Cell Lymphoma","Larynx Cancer","Bladder Cancer",[90,91,92,97,98,99],"Lymphoma","Larynx","Bladder","2026-02-05",{"date":102,"type":103},"2026-02-09","ACTUAL",{"date":105,"type":103},"2021-05-01",{"date":107,"type":84},"2029-06-18",{"name":5,"class":6},2]